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ABSTRACT
Background: Hepatitis C virus (HCV) infection is the most common cause of acute or chronic 
hepatitis in patients on hemodialysis (HD). The purpose of this study was to describe the preva-
lence of positive HCV RNA and investigate injection drug use as an emerging risk factor in pa-
tients with chronic renal disease on HD. Methods: This was a multicenter cross-sectional study 
with 325 patients with chronic renal disease on HD in the period between August 1, 2005 to 
August 30, 2006, receiving care at four institutions in the city of Porto Alegre, Southern Brazil. 
Epidemiological data were collected by means of a structured questionnaire. The following labo-
ratory tests were performed: alanine aminotransferase (ALT), anti-hepatitis C virus antibodies 
(anti-HCV), and qualitative polymerase chain reaction (PCR). Results: Of 325 patients, 68 had 
positive HCV RNA results. The comparison between patients with positive and negative PCR re-
sults revealed signifi cant differences in duration of HD (mean = 71 versus 52.4 months; p = 0.02); 
previous blood transfusion (92% versus 72%; p < 0.01); injection drug use (13% versus 0.7%; p < 
0.01); anti-HCV positivity at start of HD therapy (60% versus 4%; p < 0.01); and mean ALT value 
(39 versus 26.5; p < 0.01). Logistic regression analysis showed a positive HCV RNA independently 
associated to being on HD for more than fi ve years [OR: 2.1 (95% CI 1.2 - 3.8)]; previous blood 
transfusion [OR: 3.7 (95% CI 1.4 - 9.5)]; and injection drug use [OR: 22.6 (95% CI 4.2 - 119.6)]. 
Conclusion: Injection drug use was an independent risk factor for HCV infection among chronic 
renal disease patients on HD.
Keywords: hepatitis C virus, hemodialysis, injection drug use, risk factors.
[Braz J Infect Dis 2010;14(4):422-426]©Elsevier Editora Ltda.
INTRODUCTION
Hepatitis C virus (HCV) infection is the most 
common cause of acute or chronic hepatitis in 
patients on hemodialysis (HD). The worldwide 
prevalence of HCV viral markers among HD 
patients has been reported to range from 2.6% 
to 54%.1-5 However, studies conducted in Brazil 
have revealed an increased prevalence of HCV 
viral markers among these patients, with rates 
ranging from 5.3% to 90.4%.6-17
Parenteral exposure is an effective means 
of HCV transmission in individuals who share 
needles and syringes, receive blood or blood 
product transfusions, or have catheters insert-
ed for long-term vascular access, particularly in 
the hospital setting.3,18
Over decades, blood and blood product 
transfusion, volume transfused and dura-
tion of HD have been considered as the 
main risk factors for HCV infection in pa-
tients undergoing HD for longer than six 
months.3,19 However, the risk from these 
sources seems to have lessened,20 since blood 
and blood product transfusion have become 
safer due to improved donor screening and 
reduced need for transfusion. In this con-
text, the association between injection drug 
use and HCV infection, which has already 
been established in the general population 
and among drug addicts, arises as a pos-
sible risk factor for HCV infection in HD 
patients.2,21-34
The objective of this study was to describe 
the prevalence of positive HCV RNA and in-
vestigate injection drug use as an emerging risk 
factor in chronic renal disease patients on he-
modialysis.
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SUBJECTS AND METHODS
This was multicenter cross-sectional study with 325 patients 
with chronic renal disease on HD in the period between 
August 1, 2005 to August 30, 2006, receiving care at four 
institutions in the city of Porto Alegre, Southern Brazil. To 
be eligible, they had to be on hemodialysis for longer than 
six months, aged 18 years or more, agree to participate in 
the study, and have cognitive capacity to answer a question-
naire. 
Using a structured questionnaire, previously trained in-
terviewers, blind to laboratory results, the following infor-
mation was collected from the patients: age, sex, duration of 
HD, previous blood and/or blood product transfusions, and 
injection drug use. Creatinine levels and anti-HCV results 
at the onset of HD therapy were obtained from the patient 
records.
All study participants signed an informed consent term. 
This study was approved by the Research Ethics Committees 
of all participating institutions.
Laboratory tests
Blood samples were collected immediately before the 
HD session. The following tests were performed in all 
patients: alanine aminotransferase (ALT; dry-chemistry 
method; Johnson & Johnson); anti-HCV antibodies (an-
ti-HCV, third-generation enhanced chemiluminescence 
immunoassay; Johnson & Johnson, Amersham, Bucks, 
UK); and detection of HCV RNA by polymerase chain 
reaction (PCR; in-house method with 200 IU/mL detec-
tion limit). 
Statistical analysis
Descriptive statistics were used for univariate analysis. Strat-
ifi ed analyses were performed, when necessary, to obtain 
odds ratios (OR) and 95% confi dence intervals (95% CI) 
using the Mantel-Haenszel chi-square test. Variables signifi -
cantly associated to HCV infection at the univariate analyses 
where included in the multiple logistic regression analysis. 
The level of statistical signifi cance was set at p < 0.05.
 
RESULTS
Patient characteristics
The sample comprised 325 patients (58.2% males) with a 
mean age of 54.4 ± 15 years (ranging from 22 to 90 years). 
Mean creatinine level was 9.6 ± 3.2 mg/dL. High ALT lev-
els were observed in 12 (3.7%) patients. There were 107 
(32.9%) patients anti-HCV positive and one (0.3%) patient 
had an undetermined anti-HCV result (negative HCV RNA, 
with no history of intravenous drug use). HCV RNA was 
positive in 68 patients (21% of total sample; 63.5% of anti-
HCV positive patients). Thirty-one percent of the patients 
had been on HD for longer than fi ve years, 76% had previ-
ously undergone blood or blood product transfusions, and 
11 (3.4%) reported using injection drugs.
Comparison between PCR-positive and PCR-nega-
tive patients 
Patients who reported use of injection drugs were signifi -
cantly more likely to have positive HCV RNA results (OR = 
19.4; 95%CI 3.7 – 135.9) (Table 1). 
Table 1. Comparison of HCV RNA-positive and negative chronic renal patients on hemodialysis
Variable n (%) Positive Negative OR (95% CI) p-value OR (95% CI) 
 HCV RNA HCV RNA   adjusted
No. of patients  68 (21) 257 (79) - - -
Male sex 41 (62) 148 (57) 1.3 (0.7 to 2.4) 0.46 1.2 (0.6 to 2.1)
Age, mean ± SD 53.2 ± 14.2 54.6 ± 14.8 - 0.30 1 (0.9 to 1)
Time on hemodialysis*  71 ± 65 52.4 ± 54.6 - 0.02 2.1 (1.2 to 3.8)
(months) mean ± SD     
Blood transfusion 60 (92) 187 (72) 3.9 (1.5 to 10.5) < 0.01 3.7 (1.4 to 9.5)
Injection drug use 9 (13) 2 (0.7) 19.4 (3.7 to 135.9) < 0.01 22.6 (4.2 to 119.6)
Anti-HCV positive at  33/55 (60) 10/247 (4)  35.5 (14.5 to 89.6) < 0.01 -
start of hemodialysis
ALT (U/l), mean ± SD 39.8 ± 18.9 26.5 ± 25.5 - < 0.01 -
ALT, alanine aminotransferase; CI, confidence interval; HCV, Hepatitis C virus; OR, odds ratio; PCR, polymerase chain reaction; 
SD, standard deviation.
*For adjusted OR, time on hemodialysis > 5 years.
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Multiple logistic regression showed that being on HD for 
more than fi ve years (OR = 2.1; 95% CI 1.2 – 3.8), previous 
blood transfusion (OR = 3.7; 95% CI 1.4 – 9.5), and history of 
injection drug use (OR = 22.6; 95% CI 4.2 – 119.6) were inde-
pendent risk factors for positive HCV RNA result (Table 1).
DISCUSSION
The prevalence of anti-HCV antibodies varies greatly 
among patients on HD.1-15 In this study, 32.9% of the pa-
tients were anti-HCV positive, which is close to that de-
scribed by other authors in studies carried out in the same 
geographical region,12,14-17 but higher than the mean prev-
alence of 15.4% reported in a Brazilian national census.6 
Mean anti-HCV prevalence is below 10% in developed 
countries,1,3,35 and the increased prevalence rate observed 
in our study may reﬂ ect the poor-quality care provided to 
this population.
In the present study, 21% of all patients and 63.5% of 
the anti-HCV positive patients had positive HCV RNA re-
sults. These results are similar to those reported in Euro-
pean studies,36,37 but lower than those found in the United 
States.31,38 In comparison to other Brazilian studies, al-
though our rates are consistent with fi ndings from some 
studies,8,12 our results were lower than those reported by 
several other studies (PCR positivity between 69% and 
100% in anti-HCV positive patients).7,9,10,16,39,40 This may 
be partially explained by the fact that the PCR technique 
employed in the present study had a detection limit of 200 
IU/mL, which is less sensitive in HD patients, who often 
present low or variable viral loads. 
Sex and age were not independently associated with 
HCV infection, which is consistent with the existing 
literature.39,41,42 
Duration on HD has been described as the main inde-
pendent risk factor for HCV infection,2,3,21,35,43-45 and each 
additional year on HD represents an increase of 10% to 
13% in the risk of infection.5,46 In this study being on HD 
longer than fi ve years was an independent risk factor for 
infection, which is in agreement with fi ndings reported in 
other studies.8,10,14,37,47-50 
The introduction of erythropoietin and iron supple-
mentation in the management of anemia in patients with 
chronic renal disease has dramatically reduced the need for 
blood and blood product transfusions in this population. 
Similarly, the improvement in donor selection and the 
introduction of screening tests have reduced the risks of 
HCV infection associated with transfusion.2,19,21,51 There-
fore, the current risk rates for HCV infection in patients 
on HD may differ substantially from those reported 10 or 
15 years ago.20 
In this study, previous blood transfusion was an in-
dependent risk factor for HCV infection, according to 
the literature.48,49 Although some studies found a signifi -
cant association between blood transfusion and HCV in 
univariate analyses, this association was not sustained in 
multivariate models.37,46,47 Likewise, similar fi ndings were 
reported in Brazilian studies.8,9,13,14,39,42,50 
Some patients had HCV infection markers before they 
were started on hemodialysis therapy, which is a poten-
tially undefi ned risk factor. In this study, 14.2% (76% with 
positive HCV RNA) of all patients were anti-HCV posi-
tive before starting HD therapy, as reported in previous 
studies.20,33 Sandhu et al.34 observed that HCV infection 
was eight times greater for patients with chronic renal dis-
ease and risk behavior. 
Among the general population, injection drug use is the 
main risk factor for HCV infection and accounts for 68% of 
new cases.21 Some authors have classifi ed injection drug use 
as an additional risk factor for HCV infection in patients on 
HD.2,20,32-34,46,47 In our study, this variable was an independent 
risk factor for HCV infection, with an adjusted OR of 22.6. 
This result is in agreement with fi ndings reported by Sandhu 
et al.34 and Bergman et al.20 who found a non-adjusted OR 
of 55.3 and an adjusted OR of 6.6, respectively, and by other 
investigators.2,10,32,46,47 
Jadoul35 considers injection drug use as a risk factor, espe-
cially in American cohorts, which is supported by data from 
the Centers for Disease Control and Prevention (CDC).44 This 
author also points out that drug use seems to be less impor-
tant in European samples, as shown in studies conducted in 
Germany, France, and Belgium, where injection drug use was 
not a risk factor for HCV infection in patients on HD.37,49,52 
No similar reports analyzing this association in Latin Ameri-
can patients could be retrieved in our literature review.
In the general population,21 as well as in groups of in-
tranasal cocaine users53 and alcohol abusers,54 injection 
drug use has been shown to be an established risk factor for 
HCV infection. In our study, this association was clearly 
demonstrated in patients on HD. One possible limitation 
worth mentioning is that some patients in this study may 
not have admitted drug use, which could translate into un-
derestimation.34 
In summary, injection drug use was an important risk fac-
tor for HCV infection in this cohort of chronic renal failure 
patients on HD.
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